Joseph Birkett

Joseph Birkett has had a diverse range of roles in the pharmaceutical industry. Joseph'smost recent position was as Senior Vice President of Clinical Development at Vincerx Pharma, beginning in 2022. Prior to that, they served as the CEO of TELONOSTIX LTD. from December 2017 onwards. From 2014, they were the Director and Owner of Crest Pharma Ltd. Joseph also held the position of Chief Executive Officer at PearlRiver Bio (PRB), a Centessa company, from June 2020 until 2022.

Earlier in their career, Joseph worked as a Medical Scientist and Director of Scientific and Program Management at Acerta Pharma B.V., a member of the AstraZeneca Group, from December 2016 to January 2020. Joseph was also the European Medical Affairs Director at Acerta Pharma from December 2014 to December 2016.

Joseph's experience includes serving as a Neutral Investment Panel Member/Consultant at Life Science Ventures Ltd from July to November 2014. Before that, they held various positions at ONO PHARMA UK LTD, including Director of Oncology Drug Development Europe from April 2012 to February 2014, and Clinical Science Director from March 2011 to April 2012.

Joseph began their career as a Clinical Scientist at Roche Pharmaceuticals from February 2007 to March 2011, and as a Clinical Development Associate at Eli Lilly and Company from June 2004 to February 2007.

Joseph Birkett pursued their education from 1996 to 2000 at King's College London, where they obtained a PhD in psychiatric medicine.